PATENT CLAIM ANALYSIS

Application Number: 15979041
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-09
Patent Classification: ["514", "402000"]

Abstract:
The present invention describes methods and compositions for improving the therapeutic efficacy of therapeutic agents previously limited by suboptimal therapeutic performance by either improving efficacy as monotherapy or reducing side effects. Such methods and compositions are particularly applicable to bisantrene or derivatives, analogs, or prodrugs thereof.

Claim (Index 7):
The method of  claim 6  wherein the drug therapy comprises the administration of bisantrene and wherein the indication for use is selected from the group consisting of:\n (a) use for treatment of refractory breast cancer; \n (b) use for treatment of triple-negative breast cancer; \n (c) use for treatment of acute myelocytic leukemia (AML); \n (d) use for treatment of acute myelocytic leukemia (AML) and acute lymphocytic leukemia (ALL) of childhood; \n (e) use for treatment of myelodysplastic syndrome; \n (f) use for treatment of chronic myelocytic leukemia (CML), either subsequent to or in combination with the administration of tyrosine kinase inhibitors or homoharringtonine; \n (g) use for treatment of chronic lymphocytic leukemia; \n (h) use for treatment of Hodgkin's lymphoma; \n (i) use for treatment of non-Hodgkin's lymphoma; \n (j) use for treatment of mycosis fungoides; \n (k) use for treatment of androgen-resistant prostate cancer; \n (l) use for treatment of lung small-cell carcinoma, either subsequent to or in combination with the administration of an EGFR inhibitor, wherein the lung small-cell carcinoma is characterized by either wild-type or mutated EGFR; \n (m) use for treatment of lung non-small cell carcinoma, subsequent to or in combination with an EGFR inhibitor, wherein the lung non-small cell carcinoma is characterized by either wild-type or mutated EGFR; \n (n) use for treatment of breast cancer characterized by overexpressed Her-2-neu; \n (o) use for treatment of glioblastoma that is resistant to one or both of the following therapeutic agents: temozolomide (Temodar) or bevacizumab (Avastin), or is characterized by EGFR variant III, either alone or in combination with other therapeutic agents; \n (p) use for treatment of malignancies characterized by overexpressed topoisomerase II; and \n (q) use for treatment of malignancies characterized by overexpressed and/or mutated EGFR.

Metadata:
- Claim Count in Document: 17.0
- Percentile: 93.0
- Lexical Diversity: 1.31579
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14907728', '14907729', '13817096', '14753911', '14245738']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7895416877048808
- 35 USC 102 Novelty (BERT): 0.5339874224850449
- Combined Prediction Score: 0.7639862611828971
- Mean Citation Score: 267.787678
- Max Citation Score: 348.62634
- Similarity Product: 245.72849240232827

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test